Sionna Therapeutics
SION
122 hedge funds and large institutions have $1.82B invested in Sionna Therapeutics in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 9 closing their positions.
256% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 9
33% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 30
21% more funds holding
Funds holding: 101 → 122 (+21)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
2.43% more ownership
Funds ownership: 98.48% → 100.91% (+2.4%)
0% more capital invested
Capital invested by funds: $1.81B → $1.82B (+$7.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$12.8M |
| 2 |
SCM
Sio Capital Management
New York
|
+$11.2M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.04M |
| 4 |
JP Morgan Chase
New York
|
+$8.9M |
| 5 |
Goldman Sachs
New York
|
+$8.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$19.9M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$10.5M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$9.54M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.83M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
ProShare Advisors
Bethesda,
Maryland
| – | -$202K | -4,903 | Closed |
|
127
Balyasny Asset Management
Chicago,
Illinois
| – | -$57.8K | -1,406 | Closed |
|
|
AB
128
Amalgamated Bank
New York
| – | -$21K | -504 | Closed |
|
129
Daiwa Securities Group
Tokyo,
Japan
| – | -$6K | -149 | Closed |
|
|
ACM
130
Aster Capital Management
Dubai,
United Arab Emirates
| – | -$1.52K | -37 | Closed |
|
|
C
131
Covestor
London,
United Kingdom
| – | +$114 | +3 | New |
|
SION Hedge Fund Activity: Q1 2026 in Review
122 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Sionna Therapeutics (SION) for Q1 2026, worth a combined $1.82B — up 0.4% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SION positions and 9 closed out — a net gain of 23 holders — while 40 added to existing stakes and 30 trimmed.
The largest buyer was Jennison Associates, adding an estimated $12.8M. The largest seller was Perceptive Advisors, cutting an estimated $19.9M.
- 122 institutional investors held Sionna Therapeutics (SION) as of Q1 2026, up from 101 in Q4 2025.
- Funds reported $1.82B of Sionna Therapeutics stock for Q1 2026, up 0.4% quarter-over-quarter.
- 32 funds opened new Sionna Therapeutics positions in Q1 2026 and 9 closed out, a net change of +23 holders.
- The largest Sionna Therapeutics buyer in Q1 2026 was Jennison Associates, an estimated $12.8M added.
- The largest Sionna Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $19.9M sold.
Based on aggregated 13F filings for Q1 2026.